Scailyte

Scailyte is a TechBio company based in Basel, Switzerland, that specializes in precision medicine by leveraging single-cell data and artificial intelligence. The company developed ScaiVision, a proprietary AI-powered discovery platform that integrates high-dimensional, multi-modal single-cell and spatial omics data with longitudinal clinical outcomes. By utilizing supervised representation learning and cluster-free approaches, the platform identifies complex molecular patterns associated with clinical endpoints, such as disease diagnosis, patient stratification, and treatment responses, without requiring pre-defined cell types. This allows the company to discover novel biological signals at high resolution and translate them into clinical assets.

The company focuses primarily on immune-mediated and inflammatory diseases, with a significant flagship program in inflammatory bowel disease (IBD) and research in oncology. Scailyte's technology enables pharma and biotech partners to address challenges in drug development, such as treatment resistance and manufacturing bottlenecks, by providing high-resolution patient endotyping. Their solutions have been applied to optimize cell therapy manufacturing and develop diagnostic prototypes, including a tissue-based molecular diagnostic. Born as an ETH Zürich spin-off in 2017, the company continues to advance its diagnostic and companion diagnostic pipeline to improve precision healthcare.